Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 5 of 5 results for mosunetuzumab

  1. Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)

    Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA892

  2. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Non-Hodgkin lymphoma: diagnosis and management (NG52)

    This guideline covers diagnosing, staging and managing non-Hodgkin lymphoma (NHL) in people aged 16 years and over. It includes radiotherapy, systemic anticancer therapy and stem cell transplantation treatments for follicular, MALT, mantle cell, diffuse large B-cell, Burkitt and peripheral T-cell lymphoma.

    NICE guideline
    Published
    20 July 2016
    View recommendations

    Sections for NG52